CA2105997A1 - Methode d'inhibition d'interactions par l'intermediaire d'un ligand padgem, grace a un inhibiteur renfermant de l'acide sialique avec une liaison 2,6 - Google Patents

Methode d'inhibition d'interactions par l'intermediaire d'un ligand padgem, grace a un inhibiteur renfermant de l'acide sialique avec une liaison 2,6

Info

Publication number
CA2105997A1
CA2105997A1 CA002105997A CA2105997A CA2105997A1 CA 2105997 A1 CA2105997 A1 CA 2105997A1 CA 002105997 A CA002105997 A CA 002105997A CA 2105997 A CA2105997 A CA 2105997A CA 2105997 A1 CA2105997 A1 CA 2105997A1
Authority
CA
Canada
Prior art keywords
pdgf
dexamethasone
tissue
cell
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002105997A
Other languages
English (en)
Inventor
Bruce Furie
Barbara C. Furie
Eric Larsen
Theresa Palabrica
Susan Sajer
Gary E. Gilbert
Denisa D. Wagner
Alessandro Celi
John Erban
Rosemary Gibson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New England Medical Center Hospitals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2105997A1 publication Critical patent/CA2105997A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C07K14/70564—Selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002105997A 1991-03-11 1992-03-09 Methode d'inhibition d'interactions par l'intermediaire d'un ligand padgem, grace a un inhibiteur renfermant de l'acide sialique avec une liaison 2,6 Abandoned CA2105997A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66745391A 1991-03-11 1991-03-11
US667,453 1991-03-11

Publications (1)

Publication Number Publication Date
CA2105997A1 true CA2105997A1 (fr) 1992-09-12

Family

ID=24678287

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002105997A Abandoned CA2105997A1 (fr) 1991-03-11 1992-03-09 Methode d'inhibition d'interactions par l'intermediaire d'un ligand padgem, grace a un inhibiteur renfermant de l'acide sialique avec une liaison 2,6

Country Status (4)

Country Link
EP (1) EP0575557A1 (fr)
JP (1) JPH06508823A (fr)
CA (1) CA2105997A1 (fr)
WO (1) WO1992016612A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US5646123A (en) * 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US6117836A (en) * 1992-03-20 2000-09-12 Cor Therapeutics, Inc. Glycosylation-mediated inhibition of factor X
JPH08501569A (ja) * 1992-10-02 1996-02-20 アルバータ リサーチ カウンスル 糖質結合ペプチドの抗炎症性、免疫寛容原性、および免疫阻害性
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
DE69333346T2 (de) * 1992-10-23 2004-10-07 Inst Genetics Llc Neuartiges p- selectin ligandenprotein
WO1994011498A1 (fr) * 1992-11-16 1994-05-26 Board Of Regents Of The University Of Oklahoma Ligand clycoproteique pour la p-selectine et son procede d'utilisation
US5658880A (en) * 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5750508A (en) * 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5789385A (en) * 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5837689A (en) * 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5679321A (en) * 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
AU2361395A (en) * 1994-04-28 1995-11-29 Genetics Institute Inc. Novel P-selectin ligand protein
ATE316385T1 (de) * 1994-06-03 2006-02-15 Cbr Inst For Biomed Res Inc Zusammensetzungen zur behandlung und vorbeugung von atherosklerose
US9788539B2 (en) 2011-05-17 2017-10-17 Velico Medical, Inc. Platelet protection solution having beta-galactosidase and sialidase inhibitors
CA2887083A1 (fr) 2012-10-05 2014-04-10 Velico Medical, Inc. Solution additive plaquettaire comprenant un inhibiteur de beta-galactosidase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504470A (ja) * 1989-10-20 1993-07-15 ニューイングランド・メディカル・センター・ホスピタルズ・インコーポレーテッド Ｐａｄｇｅｍを介した細胞結合の阻害

Also Published As

Publication number Publication date
WO1992016612A2 (fr) 1992-10-01
JPH06508823A (ja) 1994-10-06
EP0575557A1 (fr) 1993-12-29
WO1992016612A3 (fr) 1992-12-23

Similar Documents

Publication Publication Date Title
AU656372B2 (en) Composition for promoting tissue repair and regeneration
Oates et al. Mitogenic effects of growth factors on human periodontal ligament cells in vitro
US6287606B1 (en) Methods of enhancing wound healing and tissue repair
CA2105997A1 (fr) Methode d'inhibition d'interactions par l'intermediaire d'un ligand padgem, grace a un inhibiteur renfermant de l'acide sialique avec une liaison 2,6
GLOBUS et al. Regulation of bovine bone cell proliferation by fibroblast growth factor and transforming growth factorβ
LEVY et al. Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells
DE69403439T2 (de) Tgf-beta zusammensetzung zum herbeiführen von knochenwachstum
US5556645A (en) Methods of enhancing wound healing and tissue repair
AU2003268260B2 (en) Agents and methods for enhancing bone formation
RU2140282C1 (ru) Композиция, стимулирующая рост остеобластов, содержащая фрпт и витамин d
JP2001506635A (ja) 骨の成長を刺激する組成物および方法
JPH01121300A (ja) 乳汁に由来するポリペプチド成長因子
JPH06511233A (ja) 骨の形成を促進するための骨成長因子および骨吸収阻害剤
Saito et al. Bone‐resorbing activity and prostaglandin E produced by human periodontal ligament cells in vitro
Gamal et al. The effect of local delivery of PDGF‐BB on attachment of human periodontal ligament fibroblasts to periodontitis‐affected root surfaces–in vitro
JP3395904B2 (ja) 創傷治癒および組織修復を高める方法
CZ282231B6 (cs) Prostředek na generování nového růstu kosti v savci
EP0420862A1 (fr) Composes pharmaceutiques contenant des desoxyribonucleosides pour la guerison des plaies.
EP1952821B1 (fr) Agent therapeutique pour la regeneration du complexe dentine-pulpe dentaire
JPH06234653A (ja) 歯周組織再生促進剤および材料
EP2460529B1 (fr) Remède et procédé thérapeutique pour maladies pulpaires
JPH07504160A (ja) 骨の再生
JPH07316066A (ja) 創傷治癒剤
JPH03502922A (ja) インターロイキン‐１蛋白質を含む局所創傷治療用製剤
Ksander et al. Exogenous transforming growth factor‐β2 enhances connective tissue formation in transforming growth factor‐β1—deficient, healing‐impaired dermal wounds in mice

Legal Events

Date Code Title Description
FZDE Discontinued